Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Refractory Follicular Lymphoma
Relapsed Follicular Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Venetoclax

Sponsor

Georgetown University

Collaborators

[object Object]
[object Object]
[object Object]